emla is the world's most widely used skin numbing cream and offers patients a tried and tested way to help numb the pain of needles.
By applying emla at home prior to the procedure (requiring upto 1 hour application ahead of procedure), there is a significant opportunity to reduce the pain and distress for you or your child when visiting a professional for a needle involving procedure.
Over 230 million people worldwide have been effectively treated with emla and it has been used successfully by hospitals & G.P. practices in the UK since 1996.
emla can be used to numb the pain of the following
- Injections
- Tattoos
- Tattoo removal
- Blood donation / tests
- Cosmetic procedures
- Botox
- Laser hair removal
- Waxing
- Circumcision
Analgesic efficacy may decline if the skin application time is more than 5 hours. Procedures on intact skin should begin soon after the occlusive dressing is removed. On the genital mucosa analgesic efficacy declines after 10–15 minutes and therefore the procedure should be commenced immediately.
Not recommended in infants.
Local anaesthetic for topical use to produce surface anaesthesia of the skin.
For topical use on the genital mucosa to facilitate the removal of warts in adults.
For topical use on the genital mucosa to facilitate the removal of warts in adults.
Known hypersensitivity to anaesthetics of the amide type or to any other component of the product.
Methaemoglobinaemia may be accentuated in patients already taking drugs known to induce the condition, e.g. sulphonamides. The risk of additional systemic toxicity should be considered when large doses of EMLA are applied to patients already using other local anaesthetics or structurally related drugs e.g. class I anti-arrhythmics such as mexiletine. Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised.
Methaemoglobinaemia may be accentuated in patients already taking drugs known to induce the condition, e.g. sulphonamides. The risk of additional systemic toxicity should be considered when large doses of EMLA are applied to patients already using other local anaesthetics or structurally related drugs e.g. class I anti-arrhythmics such as mexiletine. Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised.
Lidocaine 2.5% w/w (25 mg/g)
Prilocaine 2.5% w/w (25 mg/g)
Prilocaine 2.5% w/w (25 mg/g)
